|
Acta Biomaterialia
|
1 |
1.00 |
|
|
|
American Journal of Respiratory and Critical Care Medicine
|
1 |
0.20 |
|
|
|
Angewandte Chemie International Edition
|
1 |
0.11 |
|
|
|
Annals of the Rheumatic Diseases
|
5 |
1.26 |
|
|
|
Arthritis & Rheumatology
|
2 |
1.06 |
|
|
|
Blood
|
6 |
1.04 |
|
|
|
Brain
|
3 |
0.98 |
|
|
|
Cancer Cell
|
1 |
0.93 |
|
|
|
Cell
|
1 |
0.11 |
|
|
|
Cell Host & Microbe
|
1 |
0.75 |
|
|
|
Chemical Science
|
1 |
1.00 |
|
|
|
Circulation
|
1 |
0.08 |
|
|
|
Clinical Infectious Diseases
|
3 |
0.32 |
|
|
|
Diabetes Care
|
1 |
0.10 |
|
|
|
Environmental Research
|
1 |
0.03 |
|
|
|
Genome Research
|
1 |
0.63 |
|
|
|
Immunity
|
5 |
0.34 |
|
|
|
Journal of Biological Chemistry
|
7 |
1.61 |
|
|
|
Journal of Cell Biology
|
1 |
0.05 |
|
|
|
Journal of Clinical Endocrinology & Metabolism
|
1 |
0.59 |
|
|
|
Journal of Clinical Investigation
|
6 |
2.33 |
|
|
|
Journal of Experimental Medicine
|
9 |
3.25 |
|
|
|
Journal of Hepatology
|
1 |
0.04 |
|
|
|
Journal of Infectious Diseases
|
1 |
0.02 |
|
|
|
Journal of Physiology
|
1 |
0.06 |
|
|
|
Journal of the American Chemical Society
|
1 |
0.23 |
|
|
|
Kidney International
|
2 |
1.04 |
|
|
|
Molecular Cell
|
4 |
2.10 |
|
|
|
Nature
|
12 |
3.55 |
|
|
|
Nature Cell Biology
|
5 |
1.20 |
|
|
|
Nature Chemistry
|
1 |
0.45 |
|
|
|
Nature Communications
|
34 |
10.01 |
|
|
|
Nature Immunology
|
8 |
2.93 |
|
|
|
Nature Medicine
|
1 |
0.03 |
|
|
|
Nature Methods
|
1 |
1.00 |
|
|
|
Neuron
|
1 |
0.15 |
|
|
|
Organic Letters
|
1 |
0.38 |
|
|
|
PLOS Biology
|
3 |
2.52 |
|
|
|
PLOS Medicine
|
1 |
0.63 |
|
|
|
Plant Biotechnology Journal
|
1 |
0.61 |
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
|
15 |
7.92 |
|
|
|
Proceedings of the Royal Society B
|
1 |
0.20 |
|
|
|
Science
|
1 |
0.13 |
|
|
|
Science Advances
|
9 |
4.10 |
|
|
|
Science Translational Medicine
|
6 |
2.17 |
|
|
|
The EMBO Journal
|
9 |
4.10 |
|
|
|
The Journal of Allergy and Clinical Immunology
|
7 |
2.19 |
|
|
|
The Lancet
|
3 |
0.60 |
|
Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial
|
0.15 |
|
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study
|
0.13 |
|
Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial
|
0.32 |
|
|
The Lancet Diabetes & Endocrinology
|
2 |
1.27 |
|
|
|
The New England Journal of Medicine
|
6 |
0.72 |
|
|
|
Thorax
|
3 |
1.33 |
|
|